CancerDrs

Lung Cancer clinical trials

300 actively recruiting lung cancer trials in the United States. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Trials focus on targeted therapies, immunotherapy, and combination regimens.

Data from ClinicalTrials.gov · last refreshed · Lung Cancer stats on SEER

65
Phase 1
107
Phase 2
24
Phase 3
1
Phase 4
103
Other

Lung Cancer by the numbers (U.S.)

226,650
Estimated new cases (2025)
124,730
Estimated deaths (2025)
28.1%
5-year relative survival
71
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse lung cancer trials by state

Texas 128 California 120 New York 109 Florida 95 Ohio 81 Virginia 76 Tennessee 68 Illinois 67 Pennsylvania 66 Michigan 64 Massachusetts 63 New Jersey 56 Maryland 55 North Carolina 51 Missouri 50 Colorado 42 Arizona 41 Minnesota 41 Washington 41 Georgia 39 Oregon 37 Wisconsin 35 Kentucky 33 Connecticut 29 Indiana 27 Utah 26 Nebraska 23 Kansas 22 District of Columbia 21 Oklahoma 20 South Carolina 19 Arkansas 18 Louisiana 17 Alabama 16 Iowa 16 New Mexico 14 South Dakota 13 Montana 12 Nevada 12 Mississippi 11 North Dakota 11 Idaho 9 Rhode Island 9 West Virginia 9 Delaware 8 Hawaii 8 New Hampshire 8 Maine 7 Alaska 6 Vermont 5 Wyoming 3

Top trials by phase + site coverage

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Locations:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska

+ 1147 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Locations:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska

+ 601 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama

+ 473 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Locations:
  • Pioneer Research Center — Bullhead City, Arizona
  • Ironwood Cancer & Research Centers — Chandler, Arizona
  • Ironwood Cancer & Research Centers — Gilbert, Arizona

+ 223 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Locations:
  • Local Institution - 0487 — Mobile, Alabama
  • Southern Arizona VA Health Care System — Tucson, Arizona
  • Local Institution - 0112 — Los Angeles, California

+ 55 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06881784
Locations:
  • Alabama Oncology — Birmingham, Alabama
  • Loma Linda University — Loma Linda, California
  • MemorialCare Long Beach Medical Center — Long Beach, California

+ 50 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Locations:
  • Southern Cancer Center Pc — Daphne, Alabama
  • Mohtaseb Cancer Center & Blood Disorders — Bullhead City, Arizona
  • Palo Verde Hematology Oncology — Glendale, Arizona

+ 38 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Locations:
  • Research Site — Fountain Valley, California
  • Research Site — Los Alamitos, California
  • Research Site — Los Angeles, California

+ 34 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Locations:
  • University of California San Diego — La Jolla, California
  • UC Davis Comprehensive Cancer Center — Sacramento, California
  • University of Colorado — Aurora, Colorado

+ 34 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treat…

Sponsor: BioNTech SE
NCT ID: NCT06712355
Locations:
  • ACRC Arizona Clinical Research Center — Tucson, Arizona
  • Clermont Oncology Center — Clermont, Florida
  • Cancer Care Centers of Brevard, Inc — Palm Bay, Florida

+ 33 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…

Sponsor: Amgen
NCT ID: NCT05920356
Locations:
  • Sansum Clinic — Santa Barbara, California
  • Medical Oncology Hematology Consultants Helen F Graham Cancer Center — Newark, Delaware
  • Boca Raton Clinical Research Coral Springs — Coral Springs, Florida

+ 24 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer …

Sponsor: Bayer
NCT ID: NCT06452277
Locations:
  • Patty & George Hoag Cancer Center — Newport Beach, California
  • UC San Diego Health - Moores Cancer Center — San Diego, California
  • UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology — San Francisco, California

+ 22 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

How to read clinical trial eligibility →

Inclusion, exclusion, biomarker requirements, performance status, and prior-therapy rules.

 How to find a clinical trial →

Search strategy, matching services, and when to involve your oncologist.

 Clinical trial phases explained →

Phase 1 through 4, what each means for patients.

 Insurance coverage for clinical trials →

The ACA requires coverage of routine patient costs. How to appeal denials.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09